See more : Bolt Biotherapeutics, Inc. (BOLT) Income Statement Analysis – Financial Results
Complete financial analysis of TransMedics Group, Inc. (TMDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TransMedics Group, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sphere 3D Corp. (ANY) Income Statement Analysis – Financial Results
- COSCO SHIPPING International (Hong Kong) Co., Ltd. (0517.HK) Income Statement Analysis – Financial Results
- Globavend Holdings Limited (GVH) Income Statement Analysis – Financial Results
- Streamify AB (STREAM.ST) Income Statement Analysis – Financial Results
- New Infinity Holdings, Ltd. (NIHL) Income Statement Analysis – Financial Results
TransMedics Group, Inc. (TMDX)
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.69M | 6.21M |
| Cost of Revenue | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross Profit | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M | 2.14M | 766.00K |
| Gross Profit Ratio | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% | 27.81% | 12.34% |
| Research & Development | 63.27M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M | 14.96M | 15.64M |
| General & Administrative | 119.55M | 51.69M | 38.28M | 24.19M | 21.52M | 12.32M | 7.61M | 0.00 |
| Selling & Marketing | 0.00 | 18.21M | 8.60M | 931.00K | 2.07M | 1.02M | 674.00K | 0.00 |
| SG&A | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.32M | 7.61M | 8.12M |
| Other Expenses | 0.00 | -1.00M | -877.00K | 1.65M | 790.00K | -213.00K | 548.00K | 5.00K |
| Operating Expenses | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M | 22.56M | 23.75M |
| Cost & Expenses | 270.35M | 124.90M | 69.69M | 52.02M | 53.21M | 33.25M | 28.11M | 29.20M |
| Interest Income | 12.50M | 900.00K | 100.00K | 700.00K | 1.00M | 0.00 | 548.00K | 5.00K |
| Interest Expense | 10.79M | 3.73M | 3.87M | 3.99M | 4.35M | 2.42M | 1.07M | 979.00K |
| Depreciation & Amortization | 8.18M | 4.20M | 2.65M | 1.58M | 1.22M | 769.00K | 630.00K | 426.00K |
| EBITDA | -7.60M | -28.96M | -38.49M | -23.15M | -27.93M | -20.23M | -19.09M | -22.66M |
| EBITDA Ratio | -3.15% | -34.71% | -133.19% | -96.46% | -122.07% | -151.19% | -250.46% | -363.26% |
| Operating Income | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M | -20.43M | -22.99M |
| Operating Income Ratio | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% | -265.79% | -370.20% |
| Total Other Income/Expenses | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M | -365.00K | -1.08M |
| Income Before Tax | -26.67M | -36.17M | -44.18M | -28.72M | -33.51M | -23.72M | -20.79M | -24.07M |
| Income Before Tax Ratio | -11.04% | -38.70% | -145.99% | -112.00% | -141.95% | -182.18% | -270.54% | -387.58% |
| Income Tax Expense | -1.64M | 66.00K | 36.00K | 32.00K | 40.00K | 41.00K | 32.00K | 984.00K |
| Net Income | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M | -20.82M | -24.07M |
| Net Income Ratio | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% | -270.96% | -387.58% |
| EPS | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| EPS Diluted | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Weighted Avg Shares Out | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
| Weighted Avg Shares Out (Dil) | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
ANDOVER, Mass. , Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics...
TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
1 No-Brainer Growth Stock I Can't Wait to Buy Again if the Market Crashes
Recently, U.S. stock markets have been more volatile than usual. TransMedics stock has surged thanks to revenue that has more than doubled this year.
TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.
Betting Big On TransMedics (Q2 2024 Update)
TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and building the largest transplant logistics network in the US enhances its competitive moat. Conservative guidance,...
Can TransMedics (TMDX) Run Higher on Rising Earnings Estimates?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Q3's Rising Stars: 3 Growth Stocks for Your Must-Watch List
Over the past years, AI and GLP-1 stocks have been the major themes that have drawn the most attention. However, plenty of other investments have been working and flying under the radar in this market.
Source: https://incomestatements.info
Category: Stock Reports